Wall Street analyst estimates for Codexis, Inc. (CDXS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.09 | ||
| 2026-08-11 | $-0.13 | $-0.14 | +8.2% |
| 2026-05-07 | $-0.10 | $-0.11 | +9.1% |
| 2026-03-11 | $0.11 | $0.01 | +1000.0% |
| 2025-11-06 | $-0.22 | $-0.15 | -46.7% |
| 2025-08-13 | $-0.16 | $-0.17 | +5.9% |
| 2025-05-14 | $-0.25 | $-0.20 | -25.0% |
| 2025-02-27 | $-0.13 | $-0.04 | -225.0% |
Valuation Ratios
| Price / Book | 3.70 |
| EV / EBITDA | -9.37 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.8M | $50.0M | $60.6M | $68.5M | $69.1M | $104.8M | $138.6M | $70.1M | $59.3M | $70.4M |
| Cost of Revenue | $9.8M | $14.3M | $12.6M | $15.6M | $13.7M | $22.2M | $38.0M | $12.8M | $16.3M | $9.3M |
| Gross Profit | $39.1M | $35.7M | $48.0M | $52.8M | $55.3M | $82.5M | $100.6M | $57.3M | $43.1M | $61.0M |
| Research & Development | $22.2M | $29.7M | $30.0M | $33.9M | $44.2M | $55.9M | $80.1M | $58.9M | $46.3M | $52.3M |
| Selling, General & Admin | $25.4M | $29.0M | $29.3M | $31.5M | $35.0M | $49.3M | $52.2M | $53.2M | $55.1M | $47.1M |
| Operating Expenses | $47.6M | $58.7M | $59.3M | $65.4M | $79.2M | $105.2M | $135.4M | $125.4M | $101.6M | $99.4M |
| Operating Income | -$8.6M | -$23.0M | -$11.3M | -$12.5M | -$23.9M | -$22.7M | -$34.9M | -$68.1M | -$58.5M | -$38.3M |
| EBITDA | -$4.0M | -$21.9M | -$10.1M | -$8.0M | -$19.4M | -$15.1M | -$26.3M | -$49.3M | -$53.4M | -$33.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.8M |
| Pre-tax Income | -$8.6M | -$22.9M | -$10.9M | -$11.9M | -$23.7M | -$21.1M | -$33.3M | -$76.2M | -$65.2M | -$43.9M |
| Income Tax | -$40000 | $81000 | -$37000 | $17000 | $339000 | $189000 | $276000 | $69000 | $34000 | $47000 |
| Net Income | -$8.6M | -$23.0M | -$10.9M | -$11.9M | -$24.0M | -$21.3M | -$33.6M | -$76.2M | -$65.3M | -$44.0M |
| EPS | $-0.21 | $-0.50 | $-0.21 | $-0.21 | $-0.40 | $-0.33 | $-0.51 | $-1.12 | $-0.89 | $-0.50 |
| EPS (Diluted) | $-0.21 | $-0.50 | $-0.21 | $-0.21 | $-0.40 | $-0.33 | $-0.51 | $-1.12 | $-0.89 | $-0.50 |
| Shares Outstanding (Diluted) | $40.6M | $46.2M | $52.2M | $56.5M | $59.4M | $64.6M | $65.3M | $68.1M | $73.4M | $87.1M |
Price
| Price | $1.34 |
| Market Cap | $144M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARMP · CCCC · GNFT · IMDX · IPHA · IVVD · OABI
Explore sector: Healthcare · Biotechnology
More sections of CDXS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks